A study comparing two inhaled medicines dexmedetomidine and magnesium sulphate to see which better controls heart rate, blood pressure, and depth of anaesthesia during insertion of the breathing tube for surgery.

Evaluation of haemodynamic stability and BIS score variations following nebulised dexmedetomidine versus magnesium sulphate during laryngoscopy and tracheal intubation a double blinded randomized comparative study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106573

Enrollment

Registered

2026-03-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K36- Other appendicitis

Interventions

Intervention1: Dexmedetomidine: Group D Nebulised dexmedetomidine 1 microgram per kg diluted to 4 ml with normal saline given 20 minutes before induction. Control Intervention1: Dexmedetomidine: Grou

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA 1 and ASA 2 2.18 to 45 years undergoing elective general surgeries like 3.Modified radical mastectomy 4.Lap appendicectomy thyroidectomy 5.Lap cholecystectomy under general anaesthesia 6.BMI less than 29 or equal to 29 7.MPG 1 and 2

Exclusion criteria

Exclusion criteria: 1.ASA 3 and ASA 4 2.BMI more than 29 3. neuromuscular disease 4. hepatic and renal disease 5.allergy to drug used 6. pregnancy and lactation 7.difficult airway MPG 3 and 4

Design outcomes

Primary

Measure	Time frame
Change in haemodynamic parameters (heart rate and blood pressure) during laryngoscopy and tracheal intubationTimepoint: 1.Pre and post nebulisation 2.During laryngoscopy and tracheal intubation 3.2 minutes post intubation 4.5 minutes post intubation 5.10 minutes post intubation	—

Secondary

Measure	Time frame
BIS score variations, sedation score, and incidence of adverse effects following nebulised dexmedetomidine and magnesium sulphate during laryngoscopy and tracheal intubation.Timepoint: Baseline, after nebulization, after induction, immediately after intubation, and at 1, 3 and 5 minutes after intubation; sedation assessed before induction; adverse effects recorded intraoperatively	—

Countries

India

Contacts

Public ContactRajanalini N

Government Rajaji Hospital and Madurai Medical College

rajanalinimmc@gmail.com09788472416

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026